Soma Compound with Codeine
"Consumers and health care professionals will soon find updated labeling for extended-release and long-acting opioid pain relievers to help ensure their safe and appropriate use.
In addition to requiring new labeling on these prescript"...
Soma Compound with Codeine
Soma Compound with Codeine
- Patient Information:
Details with Side Effects
Patients should be advised to contact their health care provider if they experience any adverse reactions to Soma Compound with Codeine.
- Patients should be advised that carisoprodol may cause drowsiness and/or dizziness, and has been associated with motor vehicle accidents. pPatients should be advised to avoid taking carisoprodol before engaging in potentially hazardous activities such as driving a motor vehicle or operating machinery (see WARNINGS, Sedation).
- Patients should be advised to avoid alcoholic beverages while taking carisoprodol and to check with their doctor before taking other CNS depressants such as benzodiazepines, opioids, tricyclic antidepressants, sedating antihistamines, or other sedatives (see WARNINGS, Sedation).
- Patients should be advised that treatment with carisoprodol should be limited
to acute use (up to two or three weeks) for the relief of acute, musculoskeletal
discomfort. In the post-marketing experience with carisoprodol, cases of dependence,
withdrawal, and abuse have been reported with prolonged use. If the musculoskeletal
symptoms still persist, patients should contact their healthcare provider
for further evaluation.
- Patients should be warned that aspirin can cause epigastric discomfort, gastric and duodenal ulcers, and serious GI adverse reactions, such as bleeding, perforations, and/or obstruction of the stomach or intestines, which may result in hospitalization and death. Although serious GI bleeding can occur without warning symptoms (e.g., hematemesis, melena, hematochezia), patients should be alert for these symptoms and should seek urgent medical care if any of these indicative symptoms occur (see WARNINGS, Serious Gastrointestinal Adverse Reactions). In addition, patients should be alert for symptoms of ulcers (e.g., night time epigastric discomfort, vomiting, weight loss) and should seek medical attention if these symptoms occur. Patients who consume three or more alcoholic drinks a day should be counseled about the GI bleeding risks involved with the use of aspirin with alcohol.
- Patients should be informed of the symptoms of an anaphylactoid reaction
or anaphylaxis (e.g., hives, difficulty breathing, swelling of face or throat).
If these symptoms occur, patients should be instructed to seek immediate emergency
- Since codeine phosphate may cause drowsiness and/or dizziness, patients should be advised to assess their individual response to codeine phosphate before engaging in potentially hazardous activities such as driving a motor vehicle or operating machinery (see WARNING, Sedation).
- Patients should be advised to avoid alcoholic beverages while taking codeine phosphate and to check with their doctor before taking other CNS depressants such as other opioids, benzodiazepines, tricyclic antidepressants, sedating antihistamines, or other sedatives (see WARNINGS, Respiratory Depression and Sedation).
- Patients should be advised that codeine phosphate is a controlled substance. Codeine phosphate can result in psychological and physical dependence (see WARNING, Dependence and Tolerance).
- Codeine phosphate tablets should be placed in a secure place out of the reach of children
- Patients should be advised that opioids, including codeine phosphate, can cause constipation and appropriate measures should be taken to reduce the risk of constipation (e.g., dietary changes, laxatives).
- Patients should be advised that opioids, including codeine phosphate, have been associated with hypotension and gastrointestinal obstruction (WARNINGS, Hypotension, Gastrointestinal Obstruction).
- Patients should be advised that a subset of people who use codeine (ultra-rapid metabolizers) may convert codeine into its active metabolite, morphine, resulting that higher than expected exposure of morphine which can lead to increased opioid toxicity (see PRECAUTIONS, Ultra-rapid Metabolizers of Codeine).
- Nursing mothers using codeine should be informed that a subset of people who use codeine (ultra-rapid metabolizers) may convert codeine into its active metabolite, morphine, resulting that higher than expected exposure of morphine which can lead to toxic serum levels of morphine in infants of nursing mothers. Nursing mothers should be informed how to recognize the symptoms of morphine toxicity in their infants, such as sedation, difficulty breastfeeding, breathing difficulties, and decreased tone (see PRECAUTIONS, Ultra-rapid Metabolizers of Codeine).
Last reviewed on RxList: 12/4/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Soma Compound with Codeine Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Chronic Pain/Back Pain
Find tips and advances in treatment.